Figure 4 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

The antitumor efficacy of OX40/CD137 dual agonism is dependent upon IFNγ signaling. A, Schema representing treatment schedule of FS120m and anti-IFNγ. B, Tumor measurements at indicated timepoints after MC38 tumor implantation of the mice described in A. C, Representative plots from the tumor (left) and spleen (right) showing IFNγ⁺ cells in CD8⁺ T cells and indicated CD4⁺ T-cell populations from mice receiving the specified treatment. D, Replicate values of IFNγ⁺ cells in CD8⁺ T cells and the indicated CD4⁺ T-cell populations from the tumor, spleen, and tumor-draining lymph node of mice receiving the specified treatment. Data were analyzed by two-way ANOVA with Tukey correction for multiple comparisons (B) and ordinary one-way ANOVA with Tukey correction for multiple comparisons (D). Bars and error are mean and SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Ctrl, control; dLN, tumor-draining lymph node; MFI, mean fluorescence intensity.